LIVE WEBINAR: Tuesday, June 14, 2022, 5:00 PM – 6:00 PM Eastern Time

What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation

A 2-Part Complimentary NCPD Webinar Series

Hodgkin and Non-Hodgkin Lymphomas

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Tuesday, June 14th for this NCPD-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
Christopher R Flowers, MD, MS
Chair, Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Robin Klebig, APRN, CNP, AOCNP
Nurse Practitioner
Assistant Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from ADC Therapeutics, Incyte Corporation, and Seagen Inc.

Tuesday, June 14, 2022
5:00 PM – 6:00 PM Eastern Time
Live NCPD-accredited webinar

MODULE 1: What I Tell My Patients About the Current and Potential Role of Polatuzumab Vedotin in the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

  • Long-term findings with polatuzumab vedotin in combination with bendamustine/rituximab for patients with relapsed/refractory (R/R) DLBCL; optimal incorporation into current management algorithms
  • Available and emerging data with polatuzumab vedotin in combination with chemotherapy for previously untreated DLBCL; implications for clinical practice
  • Rates of peripheral neuropathy and other treatment-emergent adverse events (AEs) observed with polatuzumab vedotin in the R/R and up-front settings; appropriate monitoring and management strategies

MODULE 2: What I Tell My Patients About the Use of Tafasitamab/Lenalidomide in DLBCL Management

  • Mechanism of action of tafasitamab and biologic rationale for combining it with lenalidomide for DLBCL
  • Key data leading to the FDA approval of tafasitamab/lenalidomide for R/R DLBCL; role of this regimen in clinical practice
  • Early data with and ongoing and planned evaluation of tafasitamab in the first-line setting
  • Safety considerations with tafasitamab; strategies to address cytopenias and other commonly occurring AEs

MODULE 3: What I Tell My Patients About Loncastuximab Tesirine and Its Role in DLBCL Management

  • Mode of activity and structural makeup of the antibody-drug conjugate loncastuximab tesirine
  • Principal efficacy and safety findings with loncastuximab tesirine in patients with R/R DLBCL
  • Recent FDA approval of and patient selection for treatment with loncastuximab tesirine
  • Incidence, severity and management of commonly occurring AEs with loncastuximab tesirine; educating patients on the need to limit exposure to direct sunlight

MODULE 4: What I Tell My Patients About the Selection of Early-Line Therapy for Follicular Lymphoma (FL)

  • Comparative efficacy and tolerability profiles of the R2 regimen of lenalidomide/rituximab and rituximab in combination with chemotherapy for treatment-naïve FL
  • Appropriate dose, schedule and duration of lenalidomide and rituximab in the administration of R2; dose-modification and other strategies for patients experiencing toxicity
  • Optimal integration of obinutuzumab into FL treatment algorithms

MODULE 5: What I Tell My Patients About the Selection and Sequencing of Therapy
for R/R FL

  • Available data with and patient selection for idelalisib, copanlisib, duvelisib and umbralisib for FL
  • Mechanistic differences between the next-generation PI3 kinase (PI3K) inhibitor parsaclisib and currently available drugs in this class; activity of parsaclisib observed in published research
  • Incidence, severity and management of AEs associated with available and investigational PI3K inhibitors
  • Incidence of EZH2 mutations in patients with FL; key clinical trial findings with tazemetostat for previously treated FL
  • Appropriate selection of patients with and without EZH2 mutations for treatment with tazemetostat

MODULE 6: What I Tell My Patients About Investigational Bispecific Antibodies in FL Management

  • Mechanism of action of bispecific antibodies under investigation for R/R FL (eg, mosunetuzumab, glofitamab, epcoritamab)
  • Response rates and safety observed with bispecific antibody therapy for patients with multiregimen-relapsed FL
  • FDA breakthrough therapy designation and potential role for mosunetuzumab in the treatment of FL

MODULE 7: What I Tell My Patients About the Treatment of Mantle Cell Lymphoma (MCL)

  • Published clinical trial findings with and potential clinical role of lenalidomide as a component of up-front and/or maintenance therapy for MCL
  • Research database supporting the use of ibrutinib, acalabrutinib and zanubrutinib for R/R MCL
  • Key efficacy and safety findings with pirtobrutinib in patients with R/R MCL; potential role in management algorithms
  • Rationale for the investigation of PI3K inhibition for MCL; available data with and ongoing studies of parsaclisib

MODULE 8: What I Tell My Patients About the Selection and Sequencing of Therapy for Hodgkin Lymphoma (HL)

  • Long-term follow-up data with brentuximab vedotin (BV) in combination with AVD (doxorubicin, vinblastine and dacarbazine) for previously untreated advanced classical HL; selection of patients for this regimen
  • Incidence and management of peripheral neuropathy and other toxicities associated with BV for HL
  • Current role of anti-PD-1/PD-L1 antibodies in therapy for HL; monitoring and management strategies for immune-related AEs
  • Other agents and strategies under investigation for patients with R/R HL

MODULE 9: What I Tell My Patients About the Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Various Lymphoma Subtypes

  • Longer-term follow-up from clinical trials evaluating the efficacy and safety of axicabtagene ciloleucel (axi-cel), tisagenlecleucel and lisocabtagene maraleucel (liso-cel) for R/R DLBCL
  • Available and emerging results with CAR T-cell therapy as second-line treatment for patients with DLBCL; implications for routine practice
  • Principal outcomes from pivotal studies evaluating CAR T-cell therapy for FL; FDA approval of axi-cel and current role in clinical practice
  • Key efficacy and safety data with approved (brexucabtagene autoleucel) and investigational (liso-cel) CAR T-cell platforms in MCL

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of Hodgkin and non-Hodgkin lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate how patient- and disease-specific factors affect the selection and sequencing of therapies for follicular lymphoma, and provide counsel on personalized treatment recommendations.
  • Recognize the mechanisms of action of and available and emerging data with novel therapies approved for the treatment of diffuse large B-cell lymphoma, and determine the current and potential utility of these agents in clinical practice.
  • Develop an understanding of published clinical research guiding the management of newly diagnosed and relapsed/refractory (R/R) mantle cell lymphoma, and apply this information to patient-education discussions.
  • Review available efficacy and safety data with chimeric antigen receptor T-cell therapies directed at CD19, and identify patients with non-Hodgkin lymphoma for whom this approach may be appropriate either as part or outside of a clinical research study.
  • Assess recent therapeutic advances for newly diagnosed and R/R Hodgkin lymphoma, and use this information to enhance decision-making for patients.
  • Educate patients about the side effects associated with approved therapies commonly used in the management of various forms of lymphoma, and provide preventive and ameliorative strategies.
  • Recall the design of ongoing clinical trials evaluating novel investigational strategies for the treatment of Hodgkin and non-Hodgkin lymphomas, and counsel appropriately selected patients about availability and participation.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Klebig has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Flowers – Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Curio Science, Denovo Biopharma, Epizyme Inc, Foresight Diagnostics, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Janssen Biotech Inc, MEI Pharma Inc, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Seagen Inc; Research Funding: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Celgene Corporation, Cellectis, Eastern Cooperative Oncology Group, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, National Cancer Institute, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, The V Foundation for Cancer Research, Xencor, ZIOPHARM Oncology Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Incyte Corporation, and Seagen Inc.